Published 12 days ago • loading... • Updated 12 days ago

Natera’s Solomon Moshkevich on how MRD testing pinpoints cancer recurrence

Molecular residual disease testing could one day be as ubiquitous as a CT scan, says Natera’s president of clinical diagnostics.

Molecular residual disease testing could one day be as ubiquitous as a CT scan, says Natera’s president of clinical diagnostics.

12 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated11 days agoBias Distribution

100% Center

100% Center

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

medtechdive.com broke the news 12 days ago on Friday, May 29, 2026.

Sources are mostly out of (0)